The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.
Get insights from Vertex Pharmaceuticals' Q3 2025 earnings call—revenue growth, pipeline milestones, and outlook for ALYFTREK, CASGEVY, and JOURNAVX.
Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...
There are many purposes that spots and stripes serve in nature, but how they form has been more of a mystery to scientists.
The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...
Investor's Business Daily on MSN
Vertex Pharma's Mixed Quarter: How Legacy Products Drove Its Beat
Vertex stock dipped late Monday on a mixed third-quarter report, with the lion's share of its sales beat coming from its ...
Abstract: Graph scattering transform (GST) is mathematically-designed graph convolutional model that iteratively applies graph filter banks to achieve comprehensive feature extraction from graph ...
Zacks Investment Research on MSN
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
We expect Vertex Pharmaceuticals VRTX to surpass expectations when it reports its third-quarter 2025 results on Nov. 3, after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback